Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

The market for Bavencio (avelumab), the checkpoint inhibitor co-developed by Pfizer (NYSE: PFE) and Merck KGaA (MRK: DE), ...

Erbitux, Merck’s best-selling oncology drug, faces increased competition in China, while Bavencio is losing market share in the U.S. to new entrants. With no new products expected in the coming ...

Bavencio also grew in 2024 ... As you see on the slide, Merck is on a path to achieving its sustainability ambitions. The amount of people treated with our healthcare products continued to ...

Pfizer/Merck/EMD Sereno's BAVENCIO (avelumab) Overview BAVENCIO is a human antibody targeting programmed death ligand-1 (PD-L1). Preclinical studies have demonstrated its ability to activate both ...

By inhibiting the interaction between PD-L1 and PD-1 receptors, BAVENCIO helps restore T cell-mediated antitumor immunity in preclinical models. In November 2014, Merck KGaA, Darmstadt ...